Last $17.30 USD
Change Today -0.11 / -0.63%
Volume 55.4K
XNCR On Other Exchanges
Symbol
Exchange
Munich
As of 2:12 PM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

xencor inc (XNCR) Snapshot

Open
$17.52
Previous Close
$17.41
Day High
$17.57
Day Low
$17.26
52 Week High
01/20/15 - $18.89
52 Week Low
05/15/14 - $7.82
Market Cap
544.0M
Average Volume 10 Days
156.4K
EPS TTM
--
Shares Outstanding
31.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for XENCOR INC (XNCR)

Related News

No related news articles were found.

xencor inc (XNCR) Related Businessweek News

No Related Businessweek News Found

xencor inc (XNCR) Details

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions through its proprietary XmAb technology platform. The company’s lead XmAb-engineered antibodies include XmAb5871, a B-cell inhibitor, which is in Phase Ib/IIa clinical trials for the treatment of autoimmune diseases, such as rheumatoid arthritis and lupus; XmAb7195, an IgE inhibitor under Phase Ib clinical trial initiation to treat asthma and allergic diseases; and XmAb5574/MOR208, a Cytotoxic B-cell depleting product candidate that is in Phase II clinical trials for the treatment of B-cell cancers. It has a collaboration agreement with Boehringer Ingelheim International GmbH; and development and manufacturing services agreement with Catalent Pharma Solutions LLC. The company was founded in 1997 and is based in Monrovia, California.

28 Employees
Last Reported Date: 03/31/14
Founded in 1997

xencor inc (XNCR) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $363.7K
Chief Medical Officer
Total Annual Compensation: $322.5K
Chief Business Officer
Total Annual Compensation: $290.0K
Compensation as of Fiscal Year 2013.

xencor inc (XNCR) Key Developments

Xencor Mulls Acquisitions

Xencor, Inc. (NasdaqGM:XNCR), which has filed a shelf registration in the amount of $150 million, is looking for acquisitions. The company stated, “We may also use a portion of the net proceeds to acquire or invest in businesses, products and technologies that are complementary to our own, although we have no current plans, commitments or agreements with respect to any acquisitions.”

Xencor, Inc. and Novo Nordisk Enter Discovery Collaboration Using Xencor's XmAb Bispecific and Immune Inhibitor Technologies

Xencor, Inc. announced that it has entered into a collaboration and licensing agreement with Novo Nordisk to jointly discover novel biologic drug candidates for an undisclosed target by combining multiple Xencor XmAb technologies, including bispecific and immune inhibitor technologies. Xencor is eligible to receive up to approximately $175 million in upfront payments, research support, and pre-clinical and clinical development, regulatory and sales milestones, in addition to future royalties. Xencor and Novo Nordisk will use Xencor's XmAb bispecific technology to build a variety of molecular formats that can engage the target and also modulate desired immune functions using Xencor's XmAb immune inhibitor technology.

MorphoSys AG and Xencor Inc. Publish Final Results from Phase 1/2a Trial of MOR208 (XmAb5574)

MorphoSys AG and Xencor Inc. announced the publication of final results of a Phase 1/2a trial evaluating MOR208 (formerly XmAb5574) in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL). MOR208 is a potent anti-CD19 antibody with a proprietary modification to the Fc portion that is being developed to treat B-cell malignancies. MOR208 was in-licensed by MorphoSys from Xencor in 2010. The results demonstrate that the drug was well tolerated and achieved durable responses in a high risk and poor prognosis patient population with significant progression-free survival achieved: At recommended dose 12 patients (75%) had a partial response by physical exam criteria (IWCLL1996) and 6 patients (37.5%) had a partial response using additional CT criteria (IWCLL2008); Blood disease cleared in most patients, with median reduction in absolute lymphocyte count from baseline of 90.8%; and progression-free survival of up to 60 weeks for patients in extended treatment arm. The Phase 1/2a trial was designed to assess the drug's safety, tolerability, pharmacokinetic profile and preliminary anti-tumor activity. MOR208 was administered as an intravenous infusion on days 1, 4, 8, 15, and 22 of cycle 1, and on days 1, 8, 15, and 22 of cycle 2. Dose levels tested ranged from 0.3 to 12 mg/kg with an expansion to a total of 16 patients at the high dose. In total, 27 patients were enrolled, with a median age of 66 years. The patients were generally high risk: 14 patients had high-risk disease by the Rai staging system; 18 patients had chromosome abnormalities -- 10 patients with del(17p13.1) and 8 with del(11q22.3); 24 patients had IgVH unmutated disease. All of these factors lead to a poor prognosis in clinical practice. Patients had a median of 4 prior therapies, with a range of 1 to up to 13. MOR208 was generally well tolerated with no maximum-tolerated dose identified. The most common adverse events were infusion reactions, increased aspartate transaminase (AST), increased alanine aminotransferase (ALT), neutropenia, thrombocytopenia, fever, chills, and peripheral neuropathy. Infusion reactions occurred in 67% of patients, however, all were grade 1 or 2, and no reactions were seen following the first infusion. On the basis of physical exam and laboratory studies, 18 patients (66.7%) achieved a partial response (PR), and the remaining 9 patients (33.3%) achieved stable disease (SD). Adding CT criteria, 8 patients (29.6%) achieved a PR with an additional 16 patients (59.3%) achieving SD. Two patients had progressive disease by CT criteria. Evaluating only the 16 patients at the 12 mg/kg dose level, which is the recommended phase 2 dose, 12 patients (75%) had a PR by physical exam criteria and 6 patients (37.5%) had a PR by CT criteria, two of these patients achieving the PR during the maintenance phase. Blood disease cleared in most patients, with a median reduction in absolute lymphocyte count from baseline of 90.8% and a decrease in CLL cell count. Median progression-free survival (PFS) for all patients was 199 days. For the 8 patients on the extended treatment cohort, PFS was 420 days.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XNCR:US $17.30 USD -0.11

XNCR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for XNCR.
View Industry Companies
 

Industry Analysis

XNCR

Industry Average

Valuation XNCR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 97.6x
Price/Book 9.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 86.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact XENCOR INC, please visit www.xencor.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.